Oncos Therapeutics

Oncos Therapeutics Ltd. is a clinical-stage biotechnology company based in Helsinki, Finland, focused on developing targeted cancer immunotherapy products. The company is known for its lead product, ONCOS-102, which is an engineered human adenovirus designed to stimulate a systemic anti-tumor T cell response in cancer patients. Oncos Therapeutics utilizes its adenovirus-based platform to create therapies for various cancer types, including soft tissue sarcoma, ovarian cancer, and mesothelioma. Established in 2009, the company also runs an Advanced Therapy Access Program that began in 2007, providing individually tailored oncolytic virus therapies to patients who have not responded to standard treatments. This program has treated around 200 patients, demonstrating positive safety and efficacy outcomes. The scientific foundation for Oncos Therapeutics' developments lies in extensive research conducted at the University of Helsinki. As of July 2015, Oncos Therapeutics operates as a subsidiary of Targovax AS.